@article {DhallP4.008作者={罗希特迪豪提出琳德姆德尔和雷蒙吉尔和伊丽莎白和罗伯特•鲁本斯和资格成为Suneel Gupta}, title ={日常生活和生活质量改善活动措施Hoehn \ & Yahr子组晚期帕金森{\ textquoteright}年代疾病患者治疗后IPX066,延长释放carbidopa-levodopa (P4.008)},体积={88}={16}补充数量,elocation-id = {P4.008} ={2017},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述延长释放的影响carbidopa-levodopa (ER CD-LD)日常生活活动(ADL)和子组的生活质量先进的PD患者基于Hoehn \ & Yahr (H \ y)阶段。首页背景:ER CD-LD (IPX066 RYTARY {\ textregistered})是一种口服,CD-LD胶囊配方。初始峰值大约一个小时后,等离子体左旋多巴浓度维持4 {\ textendash} 5小时左右。设计/方法:ADVANCE-PD检查的有效性和安全性ER与速释(IR) CD-LD先进的PD患者。病人(n = 393)接受13周的双盲治疗与ER或红外CD-LD。基线的变化统一帕金森病评定量表(UPDRS)第二部分(ADL)分数和39-item帕金森{\ textquoteright}年代疾病问卷(PDQ-39)检查治疗每个H \ y阶段(我{\ textendash} II和III {\ textendash}(四)小组在这事后分析。结果:在整个研究中,UPDRS ADL (P \总得分(P < . 01)和PDQ-39 \ < . 05)与ER和红外显著提高。ER也产生一个数值更大,但非重大的改进从基线与红外UPDRS ADL量表在H \ y我{\ textendash}二世(平均(SD): -1.7 (3.7) ER和-0.5 (3.4)IR)和H \ y三世{\ textendash}四世为ER和[-0.9(4.1)+ 0.2(4.5)红外)子组。虽然PDQ-39总分提高数值,之间没有统计上的显著差异治疗组对H \ y我{\ textendash}二世为ER和[-2.6(12.7)+ 0.1(9.7)红外)或H \ y第三第四{\ textendash}[-5.3对ER(11.4)和-4.4(11.5)红外)子群。为H \ y三世{\ textendash}第四子群,PDQ-39迁移成绩更好了ER和红外(P \ < .04点);这种改善并不显著)在H \ y我{\ textendash}二子群。结论:与红外相比,治疗ER CD-LD倾向于产生更大的改善UPDRS ADL和PDQ-39规模H \ y我{\ textendash}二世和H \ y三世{\ textendash}第四子组。Impax实验室,研究支持:Inc.Disclosure:迪豪博士已经收到个人Impax梅尔兹,Teva,阿卡迪亚,美敦力公司,联合,IO疗法作为一个演讲者和/或顾问。 Dr. Gil has received personal compensation for activities with Impax Laboratories, Inc., as a participant in their speaker{\textquoteright}s bureau. Dr. Gil has been an investigator in clinical trials sponsored by Impax Laboratories, Inc. Dr. Lindemulder has received personal compensation for activities with Impax Laboratories Inc. as an employee. Dr. Rubens has received personal compensation for activities with Impax Laboratories, Inc., as an employee. Dr. Gupta has received personal compensation for activities with Impax Laboratories as an employee.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/88/16_Supplement/P4.008}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }